Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
Launched by BRYAN COTTON · Mar 28, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Admission to trauma service
- • Polytraumatic injuries OR pelvic/long bone fracture
- • Planned admission to trauma ICU or step-down/SIMU setting (this includes STICU, SIMU/TIMU, BICU, and BIMU)
- • Informed consent obtained
- Exclusion Criteria:
- • Prisoners (defined as those directly admitted from correctional facility)
- • Known or suspected pregnancy
- • ≥ 20% total body surface area (TBSA) burned
- • Nonsurvivable head injuries
- • Known hematologic or immunologic disorders
- • Known prehospital anticoagulant use
- • Patients initially placed on unfractionated heparin for thromboprophylaxis
- • Known allergy to Antithrombin or it's components
- • Enrollment in another interventional study unless approved by Trial Principal Investigator
About Bryan Cotton
Bryan Cotton is a distinguished clinical trial sponsor renowned for its commitment to advancing medical research and improving patient outcomes. With a strong emphasis on innovation and collaboration, the organization specializes in the development and management of clinical trials across various therapeutic areas. Bryan Cotton is dedicated to upholding the highest ethical standards and regulatory compliance, ensuring that all research is conducted with integrity and transparency. Through strategic partnerships and a focus on patient-centric approaches, the sponsor aims to accelerate the discovery of new treatments and enhance the overall quality of care in the healthcare community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Aurora, Colorado, United States
Miami, Florida, United States
Nashville, Tennessee, United States
Patients applied
Trial Officials
Bryan A Cotton, MD
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials